Vistagen Therapeutics (VTGN) EBIT Margin (2011 - 2026)
Vistagen Therapeutics (VTGN) posted EBIT Margin of 3595.05% for Q1 2026, up 44.27% sequentially from 6450.83% in Q4 2025, and down 10022839.0% YoY from N/an in Q1 2025.
Vistagen Therapeutics (VTGN) EBIT Margin (2011 - 2026) Analysis & Trends
Vistagen Therapeutics has reported EBIT Margin for 10 years, with the latest figure at 3595.05% in Q1 2026.
- Quarterly EBIT Margin fell 10022839.0% year-over-year to 3595.05% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 5678.74% (up 583834.0% YoY) and the FY2026 annual result came in at 5683.69%, up 583339.0% from the prior year.
- EBIT Margin advanced to 3595.05% in Q1 2026 per VTGN's latest filing, from 6450.83% in the prior quarter.
- Over five years, EBIT Margin peaked at 96633.33% in Q1 2025 and troughed at 42802.56% in Q1 2022.
- A 5-year average of 1958.83% and a median of 6376.36% in 2022 frame the typical range for EBIT Margin.
- The sharpest annual moves came in 2025 and 2026: EBIT Margin soared 10239932 bps in 2025, then sank 10022839 bps in 2026.
- Over 5 years, EBIT Margin stood at 5425.83% in 2022, then surged by 65 bps to 1918.25% in 2023, then tumbled by 237 bps to 6461.54% in 2024, then increased by 0 bps to 6450.83% in 2025, then soared by 44 bps to 3595.05% in 2026.
- According to Business Quant data, EBIT Margin over the past three periods registered 3595.05%, 6450.83%, and 7772.48% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 17.93% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -0.36% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.75% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -35.57% |
| 10 | Vistagen Therapeutics | 10.35 Mn | 10.35 Mn | - | -904.34% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3,595.05% |
| Dec 31, 2025 | -6,450.83% |
| Sep 30, 2025 | -7,772.48% |
| Jun 30, 2025 | -6,477.05% |
| Mar 31, 2025 | 96,633.33% |
| Dec 31, 2024 | -6,461.54% |
| Sep 30, 2024 | -7,774.32% |
| Jun 30, 2024 | -14,441.67% |
| Mar 31, 2024 | -5,765.99% |
| Dec 31, 2023 | -1,918.25% |
| Sep 30, 2023 | -2,260.00% |
| Jun 30, 2023 | -3,499.00% |
| Mar 31, 2023 | -6,953.98% |
| Dec 31, 2022 | -5,425.83% |
| Sep 30, 2022 | -1,958.49% |
| Jun 30, 2022 | -6,376.36% |
| Mar 31, 2022 | -42,802.56% |
| Dec 31, 2021 | -2,943.85% |
| Sep 30, 2021 | -3,575.42% |
| Jun 30, 2021 | -2,188.42% |